CANB:OTC-Can B Corp (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.55

Change

-0.01 (-1.82)%

Market Cap

USD 0.01B

Volume

0.03M

Avg Analyst Target

USD 1.20 (+118.26%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Can B Corp (CANB) Stock Analysis:
Based on the Can B Corp stock forecasts from 1 analysts, the average analyst target price for Can B Corp is USD 1.20 over the next 12 months. Can B Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Can B Corp is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Can B Corp’s stock price was USD 0.55. Can B Corp’s stock price has changed by +0.01 % over the past week, -0.01 % over the past month and +19.52 % over the last year.

About

Can B Corp. produces and sells cannabidiol (CBD) based products in the United States. It provides CBD products derived from hemp, including oils, creams, moisturizers, isolate, gel caps, spa products, and concentrates through its Website and vending machines, and other medical pr ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-03 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.30 (+0.62%)

USD107.81B 35.09 21.20
MKGAF MERCK Kommanditgesellschaft au..

+2.63 (+1.08%)

USD107.81B 34.64 21.20
TKPHF Takeda Pharmaceutical Company ..

-0.20 (-0.73%)

USD41.89B 10.09 0.06
SGIOF Shionogi & Co. Ltd

-1.00 (-1.46%)

USD21.50B 20.32 0.13
SGIOY Shionogi & Co. Ltd

-0.30 (-1.76%)

USD21.50B 20.22 0.13
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD20.18B 17.07 3.18
ESALF Eisai Co. Ltd

+0.50 (+0.84%)

USD17.82B 30.93 0.14
ESALY Eisai Co. Ltd

-0.44 (-0.73%)

USD17.82B 31.48 0.14
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21
TEVJF Teva Pharmaceutical Industries..

-1.16 (-12.35%)

USD9.34B 14.22 8.79

ETFs Containing CANB

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.42% 58% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.42% 57% F 33% F
Trailing 12 Months  
Capital Gain 19.52% 70% C- 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.52% 69% D+ 57% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 818.30% 94% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 818.30% 93% A 94% A
Risk Return Profile  
Volatility (Standard Deviation) 1,539.67% 8% F 8% F
Risk Adjusted Return 53.15% 87% B+ 76% C
Market Capitalization 0.01B 55% F 35% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 3.59 68% D+ 84% B
Price/Book Ratio 201.97 3% F 2% F
Price / Cash Flow Ratio -6.91 73% C 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -218.25% 20% F 7% F
Return on Invested Capital -74.96% 19% F 9% F
Return on Assets -49.51% 24% F 15% F
Debt to Equity Ratio 5.99% 55% F 70% C-
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.33 75% C 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.